Clinical Trial Update: A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push [Phase 4]

View source ↗

Summary

Phase 4 trial comparing quality of life and satisfaction in primary immunodeficiency patients using Gammanorm 165 mg/mL delivered by two devices (pump vs rapid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• Gammanorm

Snippet

Sponsor: Octapharma | Conditions: Primary Immunodeficiency | Phase 4 | Status: COMPLETED